This controversial, first-of-its-kind, algae-based drug for Alzheimer’s was approved in China. But citing financial concerns, the drugmaker is retiring it for good. Green Valley…
A decade ago, families confronting an Alzheimer’s diagnosis had little more than memory-boosting pills aimed at lessening symptoms but they didn’t halt disease progression….
After being rejected by EU regulators but approved in the U.S., UK, and several Middle Eastern countries, Alzheimer’s drug Kisunla added a new market:…
Anti-amyloid drugs like Leqembi and Kisunla are among the first FDA-approved treatments for early-stage Alzheimer’s disease. But these breakthroughs come with a tradeoff: Up…
In July 2024, European regulators rejected Eisai and Biogen’s anti-amyloid drug Leqembi for early stage Alzheimer’s. By November, they had changed their minds. Now, the…
Your genetics could make you more vulnerable to the side effects of the new class of Alzheimer’s drugs. Carrying two copies of the ApoE4…
When ancient Greek soldiers laid their mythical siege upon the city of Troy, they struggled to break through the city’s impenetrable walls. To finally…
Before Americans become eligible for Medicare at 65, they often rely on private insurance. But for people who start showing signs of Alzheimer’s in…
Anti-amyloid drugs like Leqembi and Kisunla are on the market for treating early Alzheimer’s disease, but they are expensive, difficult to access, and only…
In November of last year, Cassava Sciences announced their experimental Alzheimer’s drug simufilam failed to slow cognitive or functional decline in its 52-week Phase…
European regulators rejected Lilly’s Kisunla citing the number of ARIA-related deaths in its Phase 3 trial. The company will look to appeal the decision….
Eisai and Biogen’s Alzheimer’s drug Leqembi (generic name lecanemab) was the first fully-FDA approved disease-modifying treatment for early-stage Alzheimer’s disease in United States history,…
There currently no cure or treatment that can completely halt or reverse Alzheimer’s pathology in the brain. One of the biggest obstacles: Even after…
With the 2024 FDA approval of Eli Lilly’s Kisunla for early-stage Alzheimer’s disease, there are now two fairly similar anti-amyloid on the market in…
Would you still participate in an Alzheimer’s clinical trial if you found out that because of your genetics, you were more vulnerable to serious…